• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nature. Drugs: Lines of defence

Giuseppe

Emeritus
[Source: Nature, full text: (LINK). Extract, edited.]

Drugs: Lines of defence


Roxanne Palmer<SUP>1</SUP>
<DL><DT>Journal name: Nature <DT>Volume: 480, Pages: S9?S10 <DT>Date published: (08 December 2011) <DT>DOI: doi:10.1038/480S9a <DT>Published online 07 December 2011 </DT></DL>
<DL><DT><DT>Antiviral treatments are a critical component of an effective healthcare response to influenza, but drug resistance to the treatment-of-choice has public health officials searching for other options. <DT> <DT><DT>The influenza virus has adapted to render the first generation of flu antivirals impotent, and there are signs of resistance to newer remedies. In late August 2011, the International Society for Infectious Diseases, based in Boston, Massachusetts, reported that 25 influenza patients in eastern Australia were infected with a strain of the notorious swine flu ? influenza A (H1N1) ? resistant to the widely used drug oseltamivir (Tamiflu), made by Roche, headquartered in Basel, Switzerland. The Australian case is the largest cohort of oseltamivir-resistant flu yet reported as scientists and pharmaceutical companies explore ways to outsmart the virus.</DT><DT> </DT></DL>(?)
-
------
 
Back
Top Bottom